Treasury Risk Premium Jumps on Fed Leadership Uncertainty

Long-end yields carried a bigger risk premium as investors priced political and policy uncertainty. Meanwhile, banks braced for 24/7 equity trading, and deal/earnings headlines hit media, autos, and pharma.

TL;DR:

• 📉 Treasuries reprice higher risk premia
• 🕒 Banks wary of 24/7 trading
• 🎬 Paramount-Skydance targets WBD in $108.4B bid
• 💊 Pfizer slides on revenue forecast cut

Treasureis Reprice Higher Risk Premia

U.S. Treasuries reflected a rebuild in term premium as investors demanded more compensation to hold long-duration debt amid uncertainty around future Federal Reserve leadership and the policy path. That dynamic tends to steepen pressure at the long end and keeps rate volatility elevated, which can tighten financial conditions even without a Fed move. Traders will watch whether the repricing persists or fades once the leadership narrative clarifies. Source

Banks Wary of 24/7 Trading

Wall Street banks signaled cautious buy-in on the industry push toward round-the-clock stock trading, flagging higher operational costs, staffing demands, and heightened risk controls as key friction points. For markets, extended hours can improve access, but it also risks thinner liquidity pockets and sharper price gaps when news hits. The practical outcome for traders: expect more headline-driven moves outside the traditional session as infrastructure catches up. Source

Paramount-Skydance Targets WBD in $108.4B Bid

Paramount Skydance launched a hostile $108.4 billion offer for Warner Bros. Discovery, aiming to create a larger studio and streaming platform with more scale against dominant competitors. M&A at this size can reprice an entire sector—spreads, peer valuations, and debt assumptions move fast when “mega-deal” math enters the chat. The market will focus on financing structure, regulatory risk, and whether other bidders emerge. Source

Pfizer Slides on Revenue Forecast Cut

Pfizer shares fell after the company cut its 2025 revenue outlook, pointing to faster-than-expected erosion in COVID-related demand. The read-through is margin pressure and a tougher growth bridge, which can weigh on big-pharma sentiment and defensives that investors often lean on during risk-off tape. Traders will key in on updated pipeline cadence and cost actions as the next catalysts. Source